3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Active not recruiting
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Pancreatic Cancer Resectable
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Estrogen Receptor Positive Breast Cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
COVID-19
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Bone Metastases
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Irinotecan
58
Bevacizumab
56
Oxaliplatin
49
Leucovorin
49
Fluorouracil
49
Capecitabine
45
Cetuximab
44
pembrolizumab
23
IFL protocol
15
Nivolumab
11
regorafenib
10
Panitumumab
10
Celecoxib
8
Radiotherapy
7
Cyclophosphamide
7
atezolizumab
6
Surgical Procedures, Operative
6
Gemcitabine
6
Folfox protocol
6
Colonoscopy
6
trifluridine tipiracil drug combination
5
Neoadjuvant Therapy
5
Metformin
5
Immunohistochemistry
5
Biopsy
5
tislelizumab
4
spartalizumab
4
durvalumab
4
Trastuzumab
4
Mitomycin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colorectal Neoplasms
×
Hydroxychloroquine
×
Clear all
NCT04873895
2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1
Terminated
5 enrolled